KK4277
Phase 1Small molecule
Kyowa Kirin Co., Ltd.KK4277 is one of 9 small molecule programs targeting Cutaneous Lupus Erythematosus. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Cutaneous Lupus Erythematosus
#DrugCompanyPhaseTrials
1Xeljanz
PPrism Pharmaceuticals
Approved
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Sotyktu
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Vtama
OOrganon and Co
Phase 1
Plaquenil
Jazz PharmaceuticalsPreclinical
ICP-488
BBeijing InnoCare Pharma Tech Co., Ltd.
Phase 2
Aldara
BBausch Health Americas, Inc.
Preclinical
KK4277
Kyowa Kirin Co., Ltd.Phase 1
Elidel
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KK4277. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company